TICKERNOMICS Sign up
Last Update: 2024-03-28 02:13:39
Adverum Biotechnologies Inc. ( ADVM ) https://www.adverum.com
14.15USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
United States
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
ADVM
76.88%
SPY
32.74%
-85.76%
ADVM
SPY
92.93%
-73.00%
ADVM
SPY
224.41%
ADVM
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
1516.42
1579.74
0.48
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-12.02
452.66
18.17
-6.24
0.00
-12.52
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
-918.47
100.00
-876.51
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
9.9769
-80.68
-65.11
1.53
Other Earnings and Cash Flow Stats:
Adverum Biotechnologies Inc. ( ADVM ) Net Income TTM ($MM) is -134.81
Adverum Biotechnologies Inc. ( ADVM ) Operating Income TTM ($MM) is -139.75
Adverum Biotechnologies Inc. ( ADVM ) Owners' Earnings Annual ($MM) is 0.00
Adverum Biotechnologies Inc. ( ADVM ) Current Price to Owners' Earnings ratio is 0.00
Adverum Biotechnologies Inc. ( ADVM ) EBITDA TTM ($MM) is -133.26
Adverum Biotechnologies Inc. ( ADVM ) EBITDA Margin is -876.51%
Capital Allocation:
Adverum Biotechnologies Inc. ( ADVM ) has paid 0.00 dividends per share and bought back -2.182 million shares in the past 12 months
Adverum Biotechnologies Inc. ( ADVM ) has reduced its debt by 31.766 million USD in the last 12 months
Capital Structure:
Adverum Biotechnologies Inc. ( ADVM ) Interest-bearing Debt ($MM) as of last quarter is 75
Adverum Biotechnologies Inc. ( ADVM ) Annual Working Capital Investments ($MM) are 9
Adverum Biotechnologies Inc. ( ADVM ) Book Value ($MM) as of last quarter is 83
Adverum Biotechnologies Inc. ( ADVM ) Debt/Capital as of last quarter is 89%
Other Balance Sheet Stats:
Adverum Biotechnologies Inc. ( ADVM ) has 75 million in cash on hand as of last quarter
Adverum Biotechnologies Inc. ( ADVM ) has 24 million of liabilities due within 12 months, and long term debt 0 as of last quarter
Adverum Biotechnologies Inc. ( ADVM ) has 101 common shares outstanding as of last quarter
Adverum Biotechnologies Inc. ( ADVM ) has 0 million USD of preferred stock value
Academic Scores:
Adverum Biotechnologies Inc. ( ADVM ) Altman Z-Score is 0.82 as of last quarter
Adverum Biotechnologies Inc. ( ADVM ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Adverum Biotechnologies Inc. ( ADVM ) largest shareholder is owning shares at 0.00 ($MM) value
James Paul Scopa(an insider) Bought 100000 shares of Adverum Biotechnologies Inc. ( ADVM ) for the amount of $135000.00 on 2024-02-07
1.84% of Adverum Biotechnologies Inc. ( ADVM ) is held by insiders, and 65.31% is held by institutions
Adverum Biotechnologies Inc. ( ADVM ) went public on 2014-07-31
Other Adverum Biotechnologies Inc. ( ADVM ) financial metrics:
FCF:-98.20
Unlevered Free Cash Flow:-119.30
EPS:-1.30
Operating Margin:-918.47
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:-157.59
Beta:1.53
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Adverum Biotechnologies Inc. ( ADVM ) :
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.